The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
暂无分享,去创建一个
S. Signoretti | B. Leibovich | T. Choueiri | M. Michaelson | B. Shuch | C. Drake | D. Cella | Rajan T. Gupta | M. Allaf | S. Eggener | V. Master | M. Carducci | W. Stadler | A. Kapoor | L. Harshman | P. Lara | D. McDermott | R. Svatek | L. Wagner | N. Haas | D. Maskens | H. Patel | M. Puligandla | D. Heng | E. Singer | S. Cole
[1] P. Pierorazio,et al. Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United States. , 2019, European urology oncology.
[2] M. Allaf,et al. Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and Lymphadenectomy. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Casey,et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] L. Mariani,et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] C. Porta,et al. Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] P. Pierorazio,et al. Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma , 2018, The Journal of urology.
[7] A. Ravaud,et al. A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS). , 2018 .
[8] E. Jonasch. Updates to the Management of Kidney Cancer. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.
[9] Stephen Broderick,et al. Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer , 2018, The New England journal of medicine.
[10] Bohuslav Melichar,et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.
[11] T. Choueiri,et al. Evaluation of disease‐free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial‐level meta‐analysis , 2018, Cancer.
[12] J. Donovan,et al. Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). , 2018 .
[13] P. Pierorazio,et al. Incidence of T3a up-staging and survival after partial nephrectomy: Size-stratified rates and implications for prognosis. , 2018, Urologic oncology.
[14] K. Bensalah,et al. Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. , 2017, European urology.
[15] R. Motzer,et al. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Manola,et al. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial , 2017, JAMA oncology.
[17] J. Manola,et al. Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward , 2017, Kidney cancer.
[18] Donald A. Berry,et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. , 2017 .
[19] K. Bensalah,et al. European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma , 2016 .
[20] R. Motzer,et al. Systemic Therapy for Metastatic Renal-Cell Carcinoma. , 2017, The New England journal of medicine.
[21] P. Pierorazio,et al. Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT? , 2017, Urologic oncology.
[22] M. Smyth,et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease , 2016 .
[23] E. Bass,et al. A Systematic Review of Research Gaps in the Evaluation and Management of Localized Renal Masses. , 2016, Urology.
[24] E. Bass,et al. Distinguishing malignant and benign renal masses with composite models and nomograms: A systematic review and meta‐analysis of clinically localized renal masses suspicious for malignancy , 2016, Cancer.
[25] J. Patard,et al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. , 2016, The New England journal of medicine.
[26] J. Manola,et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial , 2016, The Lancet.
[27] E. Bass,et al. Diagnostic Accuracy and Risks of Biopsy in the Diagnosis of a Renal Mass Suspicious for Localized Renal Cell Carcinoma: Systematic Review of the Literature. , 2016, The Journal of urology.
[28] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[29] N. Farber,et al. Challenges in RCC Imaging: Renal Insufficiency, Post-Operative Surveillance, and the Role of Radiomics. , 2015, Kidney cancer journal : official journal of the Kidney Cancer Association.
[30] D. McDermott,et al. Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma , 2015, Therapeutic advances in urology.
[31] C. Sautès-Fridman,et al. Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin , 2013, Clinical Cancer Research.
[32] Wong-Ho Chow,et al. Epidemiology and risk factors for kidney cancer , 2010, Nature Reviews Urology.
[33] N. Baldini,et al. Immunogenic properties of renal cell carcinoma and the pathogenesis of osteolytic bone metastases. , 2009, International journal of oncology.
[34] J. Lam,et al. Surveillance strategies for renal cell carcinoma patients following nephrectomy. , 2006, Reviews in urology.
[35] Nicholas J Vogelzang,et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.
[36] T. Powles,et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.